Mometasone furoate/formoterol (MF/F) combination for the treatment of asthma: safety and tolerability findings from a clinical trial in severe asthma patients Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Mometasone furoate/formoterol (mf/f) combination treatment in patients with moderate-to-severe asthma: findings from a 1-yr safety trial Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017
Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Source: Eur Respir J 2008; 32: 989-996 Year: 2008
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial Source: Eur Respir J 2007; 30: 457-466 Year: 2007
Fluticasone propionate/formoterol fumarate improves asthma control and reduces exacerbations compared with fluticasone Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Lung function and symptom improvements with fluticasone propionate/salmeterol 250/50 and ipratropium/albuterol in patients with mild to moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005
QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Efficacy and safety of combined mometasone furoate/formoterol 200/10μg in persistent asthmatics Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004
Is overall asthma control being achieved? A hypothesis-generating study Source: Eur Respir J 2001; 17: 589-595 Year: 2001
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Fluticasone/salmeterol combination (FP/S) for immediate post-exacerbation treatment of childhood asthma Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005
Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe-to-very severe COPD Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005
High or standard initial dose of budesonide to control mild-to-moderate asthma? Source: Eur Respir J 2001; 17: 856-862 Year: 2001
Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study Source: Eur Respir J 2002; 20: 1378-1385 Year: 2002
Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004